Axio BioPharma has been selected as one of 12 startups joining Batch 3 of the Plug and Play Lifetech Accelerator.

Axio BioPharma is building the vendor-neutral data infrastructure for biomanufacturing. Biomanufacturing runs on a dozen enterprise systems that do not talk to each other. LIMS, MES, ELN, Historian, ERP, QMS, and more. Every tech transfer, every investigation, and every handoff between pharma sponsors and their manufacturing partners breaks on the same problem: critical process data is fragmented across organizational and technical boundaries. We are not building AI models. We are building the coordination layer that makes AI possible. Axio Lattice is a federated data platform that connects process data across sponsors and their manufacturing partners without centralizing it. Data stays in pharma's environment. Ownership never changes hands. Meaning is standardized through a neutral layer that works across every major enterprise system biomanufacturing depends on. Axio Lab is a Madison-based, non-GMP, high-throughput antibody production facility. It delivers fee-for-service campaigns to biotech and pharma teams while generating the clean, structured datasets and commercial relationships that seed Lattice deployments. We are vendor-neutral by design. Large manufacturers cannot host this network because sponsors will not put their process data on a competitor's platform. Pharma-built internal data teams cannot solve it alone because the problem is cross-organizational by definition. Axio sits between them, owned by neither, trusted by both. Headquartered in Madison, Wisconsin. Backed by operators and advisors from Catalent, CrowdStrike, Danaher, and the Allen Institute. If you are a sponsor, manufacturing partner, or technology vendor working on the data fragmentation problem, we would like to hear from you.